Amphastar Pharmaceuticals, Inc. Operating Lease Right-of-Use Assets
Amphastar Pharmaceuticals, Inc. (AMPH) had Operating Lease Right-of-Use Assets of $72.91 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $72.91M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $71.50M.
- 2026-01-31: Operating Lease, Right-of-Use Asset $27.70M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $42.93M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $72.91M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $71.50M 10-Q · filed 2026-05-07 |
| 2026-01-31 | $27.70M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $42.93M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $44.58M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $44.20M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $45.82M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $46.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $31.71M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $32.10M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $31.35M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $32.33M 10-K · filed 2025-03-03 |
| 2023-09-30 | $32.67M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $26.33M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $25.80M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $25.55M 10-K · filed 2024-02-29 |
| 2022-09-30 | $26.46M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $26.96M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $27.84M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $26.89M 10-K · filed 2023-03-01 |
| 2021-09-30 | $27.66M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $27.17M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $19.28M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $20.04M 10-K · filed 2022-03-11 |
| 2020-09-30 | $20.26M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $17.09M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $17.93M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $18.80M 10-K · filed 2021-03-15 |
| 2019-09-30 | $19.46M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $20.14M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $13.48M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |